Veeva Systems Raises Fiscal 2027 Earnings Guidance
The company reported strong second-quarter revenue of $928 million alongside an updated outlook for the 2027 fiscal year.
Updated on Oct. 23, 2026 in Corporate Finance
Live Poll
Is now a good time to diversify your portfolio if you hold a single large stock position?
Veeva Systems increased its fiscal 2027 adjusted earnings per share forecast to $9.21 and raised its revenue projection to between $3.68 billion and $3.69 billion. The company reported $928 million in second-quarter revenue on August 26, 2026.
Why it matters
The upward revision in financial guidance reflects momentum for the company as it secures new partnerships with major industry players like Amgen and IQVIA. These developments highlight the firm's expanding footprint in clinical operations and CRM software.
Veeva Systems lifted its fiscal 2027 revenue guidance to a range of $3.68 billion to $3.69 billion, up from the $3.64 billion previously estimated. The stock currently trades at a price-to-earnings ratio of 51.6.
The players
Veeva Systems
This cloud-computing company provides software solutions specifically tailored for the life sciences and pharmaceutical industries.
Amgen
This multinational biopharmaceutical company is a major developer of human therapeutics for serious illnesses.
IQVIA
This global provider of advanced analytics, technology solutions, and clinical research services serves the life sciences industry.
The details
Veeva's growth is supported by recent strategic wins, including Amgen's plan to deploy Vault CRM globally and IQVIA's selection of Veeva for clinical operations. Following the August guidance update, company shares appreciated 14.3% over a two-day span.
Timeline
June 2026: Original fiscal 2027 earnings projection issued.
August 26, 2026: Company raised guidance and reported second-quarter results.
September 15, 2026: Amgen announced plans to roll out Vault CRM worldwide.
October 13, 2026: IQVIA selected Veeva clinical applications.
November 5, 2026: Investor Day is scheduled to take place.
Market Dynamics
Veeva Systems trades at a price-to-earnings ratio of 51.6, significantly outpacing the current S&P 500 average ratio of 23.0. This valuation gap reflects investor confidence in the long-term growth trajectory of specialized enterprise software within the life sciences sector.
Investors should note that the company's valuation currently trades at a significant premium relative to the broader S&P 500 index. Maintaining this growth requires the company to successfully integrate its software solutions with major global clients like Amgen.
The takeaway
Veeva Systems continues to demonstrate significant growth through its specialized focus on the pharmaceutical software market. Investors should monitor upcoming investor updates to see if the company can sustain its current valuation and integration momentum.
What happens next
Veeva will host an Investor Day on November 5, 2026, and is scheduled to release its next earnings report later that month.
Further reading
For more on industry financial performance, explore the Corporate Finance section.
Source note: This article includes information reported by Trefis.
Live Poll
Is now a good time to diversify your portfolio if you hold a single large stock position?
